CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

ANI Pharmaceuticals offers to acquire Egetis Therapeutics for SEK 5.6 billion

By Public Technologies
  • ANI Pharmaceuticals offered to acquire Egetis Therapeutics for approximately SEK 5.6 billion (USD 560 million), expanding its rare-disease business.
  • The SEK 11.25-per-share offer represents a 27% premium to Egetis' 60-day volume-weighted average share price.
  • The transaction implies an enterprise value of approximately USD 434 million, adjusted for estimated net proceeds from Egetis' priority review voucher sale.
  • Egetis' MCT8-deficiency treatment EMCITATE has estimated peak sales potential exceeding USD 300 million in its approved indication, with patent protection into 2045.
  • Egetis' board unanimously supports the offer, backed by shareholders controlling approximately 42%; financing combines cash with new JPMorgan Chase debt.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ANI Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050133PRIMZONEFULLFEED9871006) on November 05, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk